Category Archives: Press Release

Pharmaceutical Hot Melt Extrusion Market is Expected to Be Biggest Emerging Market by 2024

The global pharmaceutical hot melt extrusion market has been researched to be marked by a very high degree of competition, as per a new analysis made by Transparency Market Research (TMR). With the presence of a telling count of participants into operation, the global pharmaceutical hot melt extrusion market could bear a fragmented landscape.

An intense level of rivalry has been expected to take shape in the foreseeable future as Gabler GmbH & Co. KG, Coperion GmbH, Xtrutech Ltd., Milacron Holdings Corp., and Leistritz AG lead the global pharmaceutical hot melt extrusion market. The report has stated that these players could substantially invest in research and development activities with a view to satisfy consumer demands through innovative products offered in the global pharmaceutical hot melt extrusion market.

Read Full Report: http://www.transparencymarketresearch.com/pharmaceutical-hot-melt-extrusion-market.html

TMR has estimated the world pharmaceutical hot melt extrusion market to clinch a rising share of US$36.4 mn by 2024 after recording a US$26.6 mn in 2015. The world pharmaceutical hot melt extrusion market could maintain a 3.90% CAGR during the forecast period. By product, twin screw extruder has been prophesied to reach a par excellence valuation of US$22.94 mn in the pharmaceutical hot melt extrusion market by the concluding forecast year. By geography, the North America pharmaceutical hot melt extrusion market could secure a grander 36.3% share under its belt by the same year.

Pharmaceutical Hot Melt Extrusion Market Exploits Versatility and Shortened Time to Market

The international pharmaceutical hot melt extrusion market has been envisaged to profit from the versatility and spread out future prospectus of the processing technology. Hot melt extrusion can empower agitator designs to become compatible with a specific application via easy optimization. Such unequalled advantages unable to be covered by conventional techniques could smartly fortify the international pharmaceutical hot melt extrusion market.

Industry players have been envisioned to largely benefit with cost-efficient production, speedier formulation development, and uninterrupted operation in the worldwide pharmaceutical hot melt extrusion market. With the emergence of the novel technology in the worldwide pharmaceutical hot melt extrusion market, manufacturers could ensure the efficacy and quality of their products. Low-cost production regions witnessing an influx of outsourced manufacturing activities have also been anticipated to significantly bolster the growth of the worldwide pharmaceutical hot melt extrusion market.

 Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19961

Pharmaceutical Hot Melt Extrusion Market Struggles with Drug/Polymer Stability

The analysts have foretold the possibility of non-compliance to regulatory requirements and quality concerns hindering the growth of the global pharmaceutical hot melt extrusion market. The major drawback of unsuccessful processing of drugs sensitive to higher temperatures could cut short the demand in the global pharmaceutical hot melt extrusion market. Limitation on the part of formulation options due to the properties of active pharmaceutical ingredient (API) and failure to furnish supplies on schedule have been prognosticated to be the other deterrents in the global pharmaceutical hot melt extrusion market.

Nonetheless, specialized API manufacturers could receive a lucrative opportunity and avail deeper penetration into the global pharmaceutical hot melt extrusion market with the advent of novel high potency API (HPAPI). More opportunities have been predicted to birth as healthcare organizations prefer competent contract manufacturing organizations (CMOs) for outsourcing manufacturing services, considering advantages such as best expertise, lean management, cost-effectiveness, and fulfillment of latest technology gap.

The information presented in this review is based on a Transparency Market Research report, titled, “Pharmaceutical Hot Melt Extrusion Market (Product Type – Twin Screw Extruder, Single Screw Extruder, Laboratory Extruder, and RAM Extruder; End User – Research Laboratory, Contract Manufacturing Organization, and Pharma Companies) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Diabetes Gastroparesis Market: Latest Trends & Insights 2025

Diabetes type 1 and type 2 are one of the most common chronic diseases prevalent in the world, affecting millions of people. One of the disorders associated with diabetes type 1 and type 2 is gastroparesis, which is characterized by the delayed emptying of the stomach. One of the major causes of gastroparesis is damage to the vagus nerve, reducing the mobility of the stomach contents. Diabetic neuropathy affects the vagus nerve, in cases where the blood glucose levels remain high over a longer duration. Diabetes gastroparesis is usually diagnosed with the help of imaging techniques such as ultrasound and x-ray, which is accompanied by the intake of radio isotopic meals containing barium, or using hematological / blood tests, and endoscopic techniques. There has been a marked increase in the prevalence of diabetes, especially in the developing countries, including China, India, Brazil, and some other Asian countries, leading to increasing incidence of diabetic neuropathy and consequent rise in diabetes gastroparesis around the world.

Obtain Report Details: http://www.transparencymarketresearch.com/diabetes-gastroparesis-market.html

The global diabetes gastroparesis market is segmented on the basis of drug class, disease indications, and distribution channels. The drug class segment of the global diabetes gastroparesis market is further segmented into antihistamines, antibiotics, anti-emetics, and others. The disease indication segment is segmented into compensated gastroparesis and gastric failure. The distribution channels segment is further segmented into hospital pharmacies, online pharmacies, retail pharmacies, and drug stores. Among the distribution channels segment, the hospital pharmacies segment is expected to dominate the global diabetes gastroparesis market during 2017-2025.

Rising prevalence of diabetes, increasing geriatric population, and sedentary lifestyle habits are some of the major factors responsible for the growth of the diabetes gastroparesis market in recent years. According to the International Diabetes Federation (IDF), and World Health Organization (WHO) statistics, in 2014, an estimated 422 million people in the world were suffering from diabetes. Also, the global prevalence rate of diabetes in adults has increased from 4.7% (of total population) in 1980, to 8.5% (of total population) in 2014. The World Health Organization (WHO) estimates that diabetes will be the 7th leading cause of death in the world by 2030. Increasing geriatric population around the world and sedentary lifestyles have led to increasing incidence of diabetic cases at an alarming rate. These are some of the major factors likely to be responsible for driving the growth of the global diabetes gastroparesis market during 2017-2025.

 Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22907

Region wise, the global diabetes gastroparesis market is segmented into five major regions – North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is expected to dominate the global diabetes gastroparesis market in 2016, owing to large patient population suffering from diabetes, and changing lifestyle habits. According to International Diabetes Federation (IDF), out of the estimated 422 million people in the world suffering from diabetes, an estimated 230 million people were living in the Asia Pacific region. Also, the geriatric population in countries of Asia Pacific region such as China, India, and Japan, are among the highest in the world, and increasing life expectancy in these countries is contributing to rise in prevalence of diabetes and diabetic neuropathy, leading to increasing incidence of diabetes gastroparesis. North America accounted for the second largest market share of the global diabetes gastroparesis market followed by Europe. However, the Middle East & Africa region is expected to register the highest CAGR in the global diabetes gastroparesis market during 2017-2025, owing to maximum incidence rate of diabetes in countries including Saudi Arabia, UAE, and Qatar.

Some of the key players in the global diabetes gastroparesis market are Medtronic, Kimberly-Clark Corporation, Abbott Laboratories, Salix Pharmaceuticals, Inc., Boston Scientific Corporation, C. R. Bard, Inc., Janssen Global Services, LLC, Cardinal Health, Inc., Alfa Wassermann SPA, Evoke Pharma, and Rhythm Pharmaceuticals, Inc., among others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

 

Air Ambulance Services Market will explore robust size & growth during 2017-2025

Ambulance services are vital for transportation in case of medical emergencies. Efficient ambulance services has led to on-time medical attention for accident victims or patients with chronic illness, emergency medication situations, etc. Air ambulances are armed with innovative medical equipment and accessories, along with skilled medical crew trained in providing initial emergency medical care to patients. Air ambulance provides the advantages over the issue of prolonged travel durations and limited remote areas reach that are faced in road ambulance services. The Federal Aviation Administration has laid down strict safety guidelines for air ambulance services. Air ambulance services are equipped with advanced life care services (ALS). Earlier, the use of ambulances were primarily in the battlefield; however, with rising incidence of several severe medical situations coupled with advanced innovation in ambulances, their utilization also started for transportation to-and-from hospitals of critical patients. Air ambulance services directly transport patients from their residence or place of accident to the health care establishment such as multispecialty hospitals.

Obtain Report Details: http://www.transparencymarketresearch.com/air-ambulance-services-market.html

On-board medical assistance, favorable policies for reimbursement, rising governmental focus for enhancing the emergency care standards, demand for better emergency health care services are expected to drive the global air ambulance services market. However, operational constraints, high costs, and air ambulance accidental incidences are projected to restrain the global air ambulance services market. High initial capital investments are expected to arrest the entry of new entrants in the market. Superior technological advancements in the on-board medical treatments have attracted the attention of major market players, and increasing number of service providers is expected to serve as huge opportunity for the growth of the global air ambulance services market. The need for maximizing the use of air ambulance assets to offer better emergency care and generation of more profitable returns is anticipated to fuel the growth of the market.

The global air ambulance services market has been segmented based on service type, transport vehicle type, and region. In terms of service type, the market has been classified into hospital services, community services, and other services. Based on transport vehicle type, the market has been segmented into helicopters, aircraft/airplane, and sea-planes. The aircraft segment has been further bifurcated into rotary wing aircraft and fixed wing aircraft. Helicopters offer certain advantages such as comparatively smaller take-off/ground area and ease in landing. These advantages are expected to reflect in increasing market share of the segment.

In terms of region, the global air ambulance services market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is expected to show continual growth owing to rising adoption of advanced health care infrastructure to create health care system experience safer and less strenuous and growing number of multispecialty hospitals. North America is projected to dominate the global air ambulance services market due to greater insurance coverage for air ambulance facilities and rising adoption of air medical transport facilities. However, inadequate number of aircrafts for emergency transport and lack of health care air services infrastructure in emerging countries are the key challenges in the development of the global air ambulance services market in developing countries.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22970

Increasing health expenditure per capita attributed to improving economic conditions, enhanced access to efficient emergency treatment, rising prevalence rate of cardiovascular diseases worldwide, proper reimbursement policies, increasing number of multinational hospitals equipped with proper air-ambulance services, strategic collaborative initiatives from major market players, and improving medical infrastructure in rural regions are fueling the growth of the global air ambulance services market.

Key players in the global air ambulance services market are Envision Healthcare Companies, Falck Danmark A/S, Rural/Metro Corporation, Air Methods, Acadian, AMR Air Ambulance, AirMed International, Express Aviation Services, and Lifeguard Air Ambulance, among others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

 

Hepatitis B Therapeutics Market: Strategies & Insights, & Recent Developments

Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and stops development of liver cancer and chronic disease caused by hepatitis B. It can cause a long term infection and put people at high risk of liver cancer and cirrhosis that may lead to death. Globally, hepatitis B is one of the major health problems that spreads by mucosal or percutaneous exposure as well as through menstrual, seminal, saliva, and vaginal fluids. Hepatitis B can occur due to sexual transmission, by having contact with sex workers and sex with multiple partners. Transmission of disease may also occur due to reuse of syringes and needles both among persons who inject drugs and in health care settings. Moreover, it may occur during surgical, medical, and dental procedures, and use of razors that are contaminated with infected blood. Infants and young children mostly get chronic hepatitis B.

Obtain Report Details: http://www.transparencymarketresearch.com/hepatitis-b-market.html

Hepatitis B Therapeutics Market: Dynamics

Limited access to treatment and diagnosis of hepatitis B in many resource constrained settings and increasing prevalence of hepatitis B infections are likely to drive the global hepatitis B therapeutics market during the forecast period. Rising awareness and increasing affordability are some of the key factors that will increase the rate of diagnosis before a person having advanced liver disease. According to the World Health Organization (WHO), infection of chronic hepatitis B is most common in infants. Rising incidence of hepatitis B infections is a major driver of the market. Less availability of antibiotics in the market and effectiveness of antivirals against hepatitis B infections is likely to propel the market during the forecast period. Prevalence of hepatitis B is increasing steadily across the globe. Medications and treatment options are highly expensive. These are the major drivers of the hepatitis B therapeutics market.

Hepatitis B Therapeutics Market: Segmentation

Based on therapy, the global hepatitis B therapeutics market has been segmented into:

  • Chemo Therapy
  • Immunosuppressant Therapy
  • Nucleoside Analogue

In terms of product type, the global hepatitis B therapeutics market has been segmented into:

  • Hepatitis B Vaccine
  • Anti-viral Drugs
  • Tenofovir
  • Entecavir

Based on distribution channel, the global hepatitis B therapeutics market has been segmented into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Hepatitis B Therapeutics Market: Region-wise Outlook

In terms of region, the hepatitis B therapeutics market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominated the hepatitis B therapeutics market owing to the high awareness levels, availability of improved infrastructure, and favorable government initiatives relating to the promotion of hepatitis B therapeutics. Europe is the second largest market for hepatitis B therapeutics driven by rising geriatric population, high rates of chronic infections in Central and Eastern Europe. Prevalence of hepatitis B is the highest in Middle East & Africa where adult population is chronically infected. According to the WHO, it is estimated that 2% to 5% of general population is affected chronically in Asia Pacific. Most people with liver cancer die within diagnosis as there are limited treatment options.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=144

Hepatitis B Therapeutics Market: Key Players

Major players operating in the global hepatitis B therapeutics market are GlaxoSmithKline plc, Bristol-Myers Squibb, Novira Therapeutics, Johnson & Johnson, Abivax SA, F. Hoffmann- La Roche, Novartis AG, and Merck & Co. The increasing competition among key players is likely to drive the global hepatitis B therapeutics market during the forecast period.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

 

Pharmerging Market Segment Forecasts up to 2024, Research Reports

Global Pharmerging Market: Snapshot

The global pharmerging market is experiencing a significant rise, especially in the emerging economies across the world. The rising prevalence of non-communicable diseases, aging population, increasing life expectancy, escalating income, surging government expenditure on health care, free trade agreement, and the constant research and development are some of the key factors behind the growth of this market.

 

With the increasing incidence rate of various diseases, the demand for highly innovative and better outcome products is also increasing, which is likely to result in a substantial growth of this market in the future. The continual innovation and advancements in the drugs for the treatment of a host of diseases are also anticipated to drive this market over the next few years. The global market for pharmerging, which stood at US$552.8 mn in 2015, is expected to rise at a CAGR of 11.30% between 2016 and 2024 and reach a value of US$1.40 bn by the end of 2024.

 Obtain Report Details: http://www.transparencymarketresearch.com/pharmerging-market.html

Pharmaceutical Products to Witness Strong Growth in Near Future

On the basis of type of product, pharmaceuticals and healthcare are the two main segments of the global market for pharmerging. The pharmaceuticals segment dominated the overall market in 2016 with a share of 65.2%. The scenario is expected to continue like this over the next few years, thanks to the significant rise in the demand for both, the branded as well as generic drugs.

Apart from this, the increasing number of innovative therapies for the treatment of various diseases at affordable price is also projected to boost this segment in the years to come. On the other hand, the healthcare segment is likely to be driven by the growing emphasis on medical devices used in the diagnosis and treatment of a number of diseases.

Based on the indication, the worldwide market for pharmerging has been classified into lifestyle diseases, cancers and autoimmune diseases, and infectious diseases. Among these, lifestyle-borne and cancer and autoimmune diseases are projected to offer lucrative opportunities for the growth of this market with attractiveness index over the forthcoming years.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8200

Asia Pacific to Remain on Top

In terms of the geography, the global pharmerging market reports its presence across Latin America, the Middle East and Africa, Asia Pacific, North America, and Europe. With a share of 53%, Asia Pacific led this market in 2016. Researchers expect this regional market to remain on the top, thanks to rapid urbanization, increasing patent expiration, and the surge in the investments for medical research. China has emerged as the key domestic market for pharmerging in Asia Pacific.

Among other regional markets for pharmerging, Europe and Latin America are likely to witness healthy growth in the near future. Technological advancements, extensive research and development practices, and the increasing awareness regarding the treatment and the management of healthcare facilities are likely to propel the Latin America market. The Europe market is predicted to be drive by the large population size, growing disease prevalence, and the increasing health expenditure in the region.

Huadong Medicine Co. Ltd., Sun Pharmaceutical Industries Ltd., Tata Consultancy Services Ltd., LUPIN, GlaxoSmithKline Plc., AstraZeneca, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Novartis AG, Merck & Co. Inc. F. Hoffmann-La Roche Ltd., Koninklijke Philips N.V., and Abbott Laboratories are the leading players in the global pharmerging market.